GlassScriptPhysician profile
Rhee W Miller
NPI 1003848649
$17,346.74
in general payments reported to CMS, 2019-2025
37 companies · $613 in 2025
The $613 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,858 · 2020: $1,747 · 2021: $2,155 · 2022: $2,439 · 2023: $3,335 · 2024: $2,199 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,308 · Travel and Lodging: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,307.69 |
| Travel and Lodging | $839.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $6,447.95 | 2019-2024 | Senza |
| Si-Bone, INC. | $3,092.80 | 2019-2023 | |
| Boston Scientific Corporation | $1,342.09 | 2019-2024 | |
| Relievant Medsystems, INC. | $1,262.68 | 2021-2023 | Intracept |
| Abbott Laboratories | $940.77 | 2019-2025 | Proclaim, Eterna, Prodigy |
| Collegium Pharmaceutical, INC. | $688.30 | 2019-2025 | Belbuca, Xtampza |
| Medtronic USA, INC. | $544.50 | 2019-2020 | |
| Biotronik Nro, INC. | $408.71 | 2024-2025 | Prospera |
| Globus Medical, INC. | $379.00 | 2025 | Senza |
| Vertiflex, INC. | $317.23 | 2019 | |
| Stimwave Technologies Incorporated | $257.06 | 2019-2022 | |
| Medtronic, INC. | $213.48 | 2022-2023 | Intellis Adaptivestim |
| Stryker Corporation | $172.01 | 2024 | Mild Device Kit |
| Forte Bio-Pharma LLC | $160.78 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Amgen INC. | $145.79 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $136.84 | 2024 | Evoke |
| Abbvie INC. | $129.84 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.19 | 2019-2025 | Relistor |
| Grt US Holding, INC. | $82.72 | 2021-2022 | |
| Allergan, INC. | $82.02 | 2021 | |
| Arbor Pharmaceuticals, INC. | $60.19 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $41.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.45 | 2022 | |
| Pfizer INC. | $30.53 | 2019 | |
| Mdd US Operations, LLC | $29.17 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $28.32 | 2021 | |
| Vertical Pharmaceuticals, LLC | $26.45 | 2019 | |
| Foundation Fusion Solutions, LLC | $25.64 | 2025 | |
| Scilex Pharmaceuticals INC. | $24.77 | 2022 | |
| Baudax Bio INC. | $23.54 | 2022 | |
| Masimo Corporation | $22.55 | 2023 | Patient Safetynet System |
| Almatica Pharma LLC | $17.97 | 2021 | |
| Spr Therapeutics, INC | $17.45 | 2021 | |
| Kaleo, INC. | $16.82 | 2019 | |
| Assertio Therapeutics, INC. | $14.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2023 | Seglentis |
| Horizon Therapeutics Plc | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhee Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.